ViewReleaseInStandardHtml

ExpreS2ion Biotechnologies Announces Research License Agreement with Mitsubishi Tanabe Pharma Corporation

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, has signed a two-year Research License Agreement granting Mitsubishi Tanabe Pharma Corporation access to use ExpreS2ion’s proprietary protein expression platform, ExpreS2 TM , in their Research and Development (R&D).

The Research License Agreement

The Research License Agreement grants Mitsubishi Tanabe Pharma Corporation the right to conduct research using ExpreS2ion’s proprietary ExpreS2system for two years. ExpreS2ion and Mitsubishi Tanabe Pharma Corporation are not disclosing any terms for the Research License Agreement.

The agreement follows an initial period, in which Mitsubishi Tanabe Pharma Corporation commissioned service work at ExpreS2ion by applying the ExpreS2system to solve production needs to support research on an undisclosed protein.

CEO Dr. Steen Klysner comments

We are pleased that our ExpreS2 TM platform will now be part of the R&D toolbox at Mitsubishi Tanabe Pharma Corporation. Mitsubishi Tanabe Pharma Corporation is a strong and highly renowned Japanese pharma company, and our platform now has a possibility to sustain their innovation and generation of new projects“.


Certified Adviser

Sedermera Fondkommission

E-mail: CA@sedermera.se

Telephone: +46 40-615 14 10

For further information about ExpreS2ion, please contact:

Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017.